Q
Qu Biologics
Restores innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease
About Qu Biologics
Qu Biologics Inc. is a private, clinical-stage biotechnology company based in Vancouver, Canada, focused on developing treatments for diseases linked to chronic inflammation. Founded in 2007 by Dr. Hal Gunn and Rob Freeman, the company is pioneering a novel immunotherapy platform called Site Specific Immunomodulators (SSIs). Dr. Gunn, who serves as CEO, is a physician-entrepreneur with a long-standing interest in the body's innate healing capacities. His journey began after witnessing a remarkable recovery in a pancreatic cancer patient who developed a severe infection, leading him to hypothesize that activating the innate immune system could combat chronic diseases. Before founding Qu Biologics, Dr. Gunn co-founded InspireHealth, Canada's foremost supportive cancer care center, and he holds a Doctorate of Medicine from the University of British Columbia.
The company's core business revolves around its proprietary SSI platform, which is designed to restore normal immune function in specific organs. Unlike immunotherapies that target a single pathway, SSIs are developed to stimulate and 'train' the body's innate immune system, directing activated immune cells to a targeted organ to resolve the underlying immune dysfunction. The technology is based on the 'hygiene hypothesis,' which links a decline in acute infections to a rise in immune-related diseases. SSIs are composed of components from inactivated bacteria that are typically associated with infections in the target organ, aiming to mimic the beneficial training effects of an infection without causing illness. For example, QBECO, which targets the gastrointestinal tract, is derived from E. coli, while QBKPN targets the lungs and is derived from K. pneumoniae. The treatments are designed for self-administration via subcutaneous injection.
Qu Biologics is a clinical-stage company, generating data through a series of clinical trials rather than commercial revenue. The company serves patients with conditions such as cancer (lung, colon), inflammatory bowel disease (Crohn's disease, ulcerative colitis), and immunosenescence (age-related immune decline). Qu Biologics has completed several Phase 2 clinical trials and has others underway to evaluate the safety and efficacy of its SSI treatments. As a private entity, the firm's operations are financed through equity funding from angel investors, family offices, and high-net-worth individuals, along with non-dilutive funding from grants. The company has raised approximately $29.8M in total funding, including a $12M Series C round in March 2022, to advance its clinical programs and expand its team.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Nov 2023 | $293K | — | Canadian Institutes of Health Research | ↗ |
| GRANT✓Other financing | Oct 2022 | $6.7M | — | National Research Council Canada | ↗ |
Growth signals
Latest recorded traffic for Qu Biologics is 2.5K monthly website visits, up 127.3% over the last three months. Qu Biologics's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qu Biologics in the Vancouver ecosystem
The Qu Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Research Council Canada
Canadian Institutes of Health Research
Series B and later1 investor entered at this stage
Asian Capital Alliance
Other known investors3 additional known investors
Curitas Ventures
Dave Lopez
Harmonix
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qu Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qu Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









